Biotechnology News and Research

RSS

New approach aims to prevent brain cancer recurrence by attacking tumors at the source

Researchers at the Cedars-Sinai Maxine Dunitz Neurosurgical Institute and Department of Neurosurgery identified immune system targets on cancer stem cells - cells from which malignant brain tumors are believed to originate and regenerate - and created an experimental vaccine to attack them.

6 Jan 2014

Portage acquires approximately 54% equity in Biohaven

Portage Biotech Inc., is pleased to announce that it has acquired approximately 54% equity in Biohaven Pharmaceutical Holding Company Limited, a private corporation formed under the laws of the British Virgin Islands, for $3.5 million, payable as $1.75 million upfront and the balance in three installments over the next eleven months.

6 Jan 2014

FDA grants orphan drug designation for DiaVacs' type 1 diabetes mellitus therapy

DiaVacs, Inc. announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for the company's type 1 diabetes mellitus (T1DM) therapy.

6 Jan 2014

Astellas, ClearPath announce strategic partnership to develop vaccine for infectious diseases

Astellas Pharma Inc. (Astellas) and ClearPath Development Company (ClearPath) announced today a strategic partnership to form a portfolio of development companies focused on vaccines targeting infectious diseases.

6 Jan 2014

Metabolon raises $15 million in Series E financing

Metabolon, Inc., a world leader in metabolomics-based diagnostic tests and research services, announced today that it has raised $15 million in a Series E financing through the issuance of preferred stock.

3 Jan 2014

Marina Biotech, Mirna modify license agreement regarding development of microRNA-based therapeutics

Marina Biotech, Inc., a leading oligonucleotide-based drug discovery and development company, and Mirna Therapeutics, Inc., a privately-held biotechnology company pioneering microRNA replacement therapy for cancer, announced today that they have amended their license agreement regarding the development and commercialization of microRNA-based therapeutics utilizing Mirna's proprietary microRNAs and Marina Biotech's novel SMARTICLES liposomal delivery technology.

3 Jan 2014

Rainbow Coral to hunt for new innovations, potential partnerships at Biotech Showcase

Executive leadership from Rainbow Coral Corp., a fast-rising biotechnology company, will scout for new innovations and potential partnerships this month at the sixth annual Biotech Showcase in San Francisco.

3 Jan 2014

Overweight minority women less aware of the increased risk of cardiovascular disease

Minority women tend to be less aware of the increased risk of cardiovascular disease they face by being overweight or obese. The results of a study that compared Hispanic and non-Hispanic white women based on their knowledge of heart disease risk factors and their perceptions of their own weight is published in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.

3 Jan 2014

Amgen announces romosozumab Phase 2 trial results in postmenopausal women with low BMD

Amgen and UCB (Euronext Brussels:UCB) today announced results from a Phase 2 trial evaluating romosozumab (AMG 785/CDP7851) in postmenopausal women with low bone mineral density (BMD).

2 Jan 2014

BBC TV report profiles NW Bio's DCVax-L Phase III trial for GBM brain cancer

Northwest Biotherapeutics, Inc.("NW Bio"), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that the British Broadcasting Company (BBC) TV network has broadcast a report profiling the first European patient in the Company's Phase III clinical trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM), the most common and aggressive form of brain cancer.

31 Dec 2013

Cardio3 BioSciences to participate in forthcoming Annual JP Morgan Healthcare Conference

Cardio3 BioSciences, a leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, announces its participation in the forthcoming Annual JP Morgan Healthcare Conference in San Francisco, on January 13 to 16, 2014.

30 Dec 2013

BioCryst receives $2.5M to advance development of BCX4430 for Marburg virus disease treatment

BioCryst Pharmaceuticals, Inc. today announced that the National Institute of Allergy and Infectious Diseases has exercised an option to conduct the investigational new drug enabling program and to submit an IND.

30 Dec 2013

CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its subsidiary OphthaliX Inc. released results from a 24 week, placebo-controlled phase III study involving 237 patients with moderate-to-severe Dry Eye Syndrome who were treated with its licensed drug CF101, an A3 adenosine receptor agonist.

30 Dec 2013

New Jersey ranked last in efforts to control smoking and tobacco use by children

The Campaign for Tobacco-Free Kids, a coalition of public health organizations, has ranked New Jersey 51 in the nation, including Washington D.C., in protecting children from smoking and tobacco use.

27 Dec 2013

FNIH Biomarkers Consortium announces initial results of I-SPY 2 trial for breast cancer

The I-SPY 2 TRIAL, a randomized phase II clinical trial for breast cancer launched through a unique partnership with the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium and sponsored by QuantumLeap Healthcare Collaborative has graduated the first two drugs from its innovative, multidrug standing platform trial.

27 Dec 2013

Concussion involving momentary loss of consciousness may be related to buildup of Alzheimer's

A new study suggests that a history of concussion involving at least a momentary loss of consciousness may be related to the buildup of Alzheimer's-associated plaques in the brain.

27 Dec 2013

Oramed Pharmaceuticals to purchase $15,800,000 shares in registered direct offering

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, today announced that it has entered into definitive agreements with investors to purchase an aggregate of 1,580,000 shares of common stock at a price of $10.00 per share in a registered direct offering.

26 Dec 2013

Ikaria shareholders to sell Commercial Business to Madison Dearborn Partners

Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients, announced today that its investor group and employee shareholders have reached a definitive agreement to sell the Commercial Business to Madison Dearborn Partners in a transaction valued at approximately $1.6 billion.

26 Dec 2013

Fluidigm announces universal sample prep workflow for single-cell DNA sequencing

Fluidigm Corporation today announced a universal sample prep workflow for single-cell DNA sequencing that runs on its C1TM Single-Cell Auto Prep System. This workflow streamlines targeted, whole exome and whole genome sequencing in heterogeneous cell populations and enables researchers to discover and screen somatic mutations, such as SNP, small indels, and translocations.

24 Dec 2013

AmpliPhi BioSciences completes sale of $18M of common stock in private placement financing

AmpliPhi BioSciences Corporation, the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that it has completed the sale of approximately $18 million of common stock in a private placement financing. The Company has issued an aggregate of 72,007,000 shares of the Company's common stock at a price per share of $0.25. Net proceeds from the placement are approximately $16.9 million.

24 Dec 2013

Biotechnology News and Research

New approach aims to prevent brain cancer recurrence by attacking tumors at the source

Portage acquires approximately 54% equity in Biohaven

FDA grants orphan drug designation for DiaVacs' type 1 diabetes mellitus therapy

Astellas, ClearPath announce strategic partnership to develop vaccine for infectious diseases

Metabolon raises $15 million in Series E financing

Marina Biotech, Mirna modify license agreement regarding development of microRNA-based therapeutics

Rainbow Coral to hunt for new innovations, potential partnerships at Biotech Showcase

Overweight minority women less aware of the increased risk of cardiovascular disease

Amgen announces romosozumab Phase 2 trial results in postmenopausal women with low BMD

BBC TV report profiles NW Bio's DCVax-L Phase III trial for GBM brain cancer

Cardio3 BioSciences to participate in forthcoming Annual JP Morgan Healthcare Conference

BioCryst receives $2.5M to advance development of BCX4430 for Marburg virus disease treatment

CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome

New Jersey ranked last in efforts to control smoking and tobacco use by children

FNIH Biomarkers Consortium announces initial results of I-SPY 2 trial for breast cancer

Concussion involving momentary loss of consciousness may be related to buildup of Alzheimer's

Oramed Pharmaceuticals to purchase $15,800,000 shares in registered direct offering

Ikaria shareholders to sell Commercial Business to Madison Dearborn Partners

Fluidigm announces universal sample prep workflow for single-cell DNA sequencing

AmpliPhi BioSciences completes sale of $18M of common stock in private placement financing

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News